NSCLC Clinical Trials in Irving, Texas

4 studies are recruiting for nsclc in Irving, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

    The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    NEXT Oncology - Dallas, Irving, Texas
    Locations
    20 in total
    Run by
    Tubulis GmbH

    See if you can join NCT06657222 on ClinicalTrials.gov

  2. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    NEXT Dallas, Irving, Texas
    Locations
    9 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT07397338 on ClinicalTrials.gov

  3. Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

    TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    NEXT Dallas, Irving, Texas
    Locations
    18 in total
    Run by
    Tango Therapeutics, Inc.

    See if you can join NCT06922591 on ClinicalTrials.gov

  4. A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

    The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Next Oncology, Irving, Texas
    Locations
    11 in total
    Run by
    Incendia Therapeutics

    See if you can join NCT05753722 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.